Pharmaceutical

FORE Biotherapeutics raises funding to expedite plixorafenib development

FORE Biotherapeutics has raised $75m in its Series D investment round led by SR One to expedite the clinical development of plixorafenib.

Aug 24, 2023 - 20:00
FORE Biotherapeutics raises funding to expedite plixorafenib development
FORE Biotherapeutics has raised $75m in its Series D investment round led by SR One to expedite the clinical development of plixorafenib.
Read the original article

Tags:

Previous Article

XNK partners with Swedish hospital to develop AML therapy

Next Article

Japan grants patent for BioArctic’s Parkinson’s disease antibody

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA accepts Regeneron’s BLA for linvoseltamab for review

FDA accepts Regeneron’s BLA for linvoseltamab for review

Feb 22, 2024

Bacterial infection may be a “key event” in triggering endometriosis development

Bacterial infection may be a “key event” in triggering ...

Jun 21, 2023

PXS-4728 by Syntara for Sleep Disorders: Likelihood of ...

Jan 25, 2024